Compare GIII & PGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GIII | PGEN |
|---|---|---|
| Founded | 1956 | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Apparel | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 1.4B |
| IPO Year | 2006 | 2013 |
| Metric | GIII | PGEN |
|---|---|---|
| Price | $32.36 | $4.39 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 5 | 5 |
| Target Price | ★ $29.00 | $8.33 |
| AVG Volume (30 Days) | 360.4K | ★ 3.0M |
| Earning Date | 06-05-2026 | 05-13-2026 |
| Dividend Yield | ★ 1.29% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 1.51 | N/A |
| Revenue | ★ $2,957,012,000.00 | $230,981,000.00 |
| Revenue This Year | N/A | $1,115.92 |
| Revenue Next Year | N/A | $81.04 |
| P/E Ratio | $20.97 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $20.33 | $1.28 |
| 52 Week High | $34.83 | $5.47 |
| Indicator | GIII | PGEN |
|---|---|---|
| Relative Strength Index (RSI) | 62.68 | 56.75 |
| Support Level | $25.11 | $3.96 |
| Resistance Level | $34.83 | $4.40 |
| Average True Range (ATR) | 1.10 | 0.26 |
| MACD | 0.16 | -0.00 |
| Stochastic Oscillator | 93.42 | 47.28 |
G-III Apparel Group Ltd is an apparel manufacturing company. The company makes a wide range of apparel, footwear, and accessories that sells under its own brands, licensed brands, and private-label brands. It has a substantial portfolio for licensed and proprietary brands, anchored by brands: DKNY, Donna Karan, Karl Lagerfeld, Karl Lagerfeld Paris, Vilebrequin, and others. The reportable segments of the company are Wholesale Operations and Retail Operations. The Wholesale operations segment includes sales of products under brands licensed by from third parties, and sales of products under its own brands and private label brands. The retail operations segment consists of Wilsons Leather, G.H. Bass, and DKNY retail stores. It derives majority of its revenue from Wholesale operations.
Precigen Inc is a commercial-stage biopharmaceutical company focused on developing precision medicines to improve the lives of patients, targeting immuno-oncology, autoimmune disorders, and infectious diseases using its proprietary and complementary technology platforms. These platforms support the development of gene programs, delivery through viral, non-viral, and microbe-based approaches, and control of gene expression for safety and efficacy. Its key platforms include AdenoVerse immunotherapy and UltraCAR-T, supported by the UltraPorator device for rapid and cost-effective manufacturing. Its clinical pipeline includes PRGN-2009, PRGN-3005, PRGN-3006, and PRGN-3007. Its reportable segments are Biopharmaceuticals and Exemplar.